AstraZeneca completes Atacand divestment to Cheplapharm
The total value of all payments for the Atacand brand is $400m
Read More
Tag: Cheplapharm
AstraZeneca sells Atacand rights to Cheplapharm
AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
